Nuclear magnetic resonance detects phosphoinositide 3-kinase/AKT- independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts

Neoplasia

Volumn 11, Issue 12, 2009, Pages 1301-1308

  Romanska, Hanna M ^a   Tiziani, Stefano ^a,b   Howe, Rachael C ^a   Günther, Ulrich L ^a   Gulzar, Zulfiqar ^c   Lalani, El Nasir ^d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BURNHAM INSTITUTE   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CHOLINE; GLYCEROPHOSPHORYLCHOLINE; INOSITOL PHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPID; PHOSPHORYLCHOLINE; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYONAL CARCINOMA STEM CELL; EMBRYONIC STEM CELL; METABOLISM; METABOLITE; MOUSE; MOUSE EMBRYO; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 72949106484     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09850     Document Type: Article

References (50)

1. Takahashi K, Ichisaka T, and Yamanaka S (2006). Identification of genes involved in tumor-like properties of embryonic stem cells. Methods Mol Biol 329, 449-458.
2. Wang Y and Armstrong SA (2008). Cancer: inappropriate expression of stem cell programs? Cell Stem Cell 2, 297-299.
3. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, and Weinberg RA (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40, 499-507.
4. Takahashi K, Mitsui K, and Yamanaka S (2003). Role of ERas in promoting tumour-like properties in mouse embryonic stem cells. Nature 423, 541-545.
5. Turner WS, Seagle C, Galanko JA, Favorov O, Prestwich GD, Macdonald JM, and Reid LM (2008). Nuclear magnetic resonance metabolomic footprinting of human hepatic stem cells and hepatoblasts cultured in hyaluronan-matrix hydrogels. Stem Cells 26, 1547-1555.
6. Ackerstaff E, Glunde K, and Bhujwalla ZM (2003). Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 90, 525-533.
7. Glunde K, Jie C, and Bhujwalla ZM (2004). Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 64, 4270-4276.
8. Ackerstaff E, Pflug BR, Nelson JB, and Bhujwalla ZM (2001). Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 61, 3599-3603.
9. Tiziani S, Lodi A, Khanim FL, Viant MR, Bunce CM, and Günther UL (2009). Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PLoS ONE 4, e4251.
10. 1H NMR-based metabolomics. Neoplasia 11, 269-276.
11. Aboagye EO and Bhujwalla ZM (1999). Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59, 80-84.
12. Ronen SM, Jackson LE, Beloueche M, and Leach MO (2001). Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 84, 691-696.
13. Iorio E,Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, et al. (2005). Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 65, 9369-9376.
14. Glunde K and Bhujwalla ZM (2007). Choline kinase α in cancer prognosis and treatment. Lancet Oncol 8, 855-857.
15. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez dMV, Cejas P, Skrzypski M, Gallego-Ortega D, de Castro J, Casado E, et al. (2007). Expression of choline kinase α to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 8, 889-897.
16. Nimmagadda S, Glunde K, Pomper MG, and Bhujwalla ZM (2009). Pharmaco-dynamic markers for choline kinase down-regulation in breast cancer cells. Neoplasia 11, 477-484.
17. Choi MG, Kurnov V, Kersting MC, Sreenivas A, and Carman GM (2005). Phosphorylation of the yeast choline kinase by protein kinase C. Identification of Ser25 and Ser30 as major sites of phosphorylation. J Biol Chem 280, 26105-26112.
18. Ramirez de Molina A, Penalva V, Lucas L, and Lacal JC (2002). Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 21, 937-946.
19. Jansen JF, Shamblott MJ, van Zijl PC, Lehtimaki KK, Bulte JW, Gearhart JD, and Hakumaki JM (2006). Stem cell profiling by nuclear magnetic resonance spectroscopy. Magn Reson Med 56, 666-670.
20. Solter D, Shevinsky L, Knowles BB, and Strickland S (1979). The induction of antigenic changes in a teratocarcinoma stem cell line (F9) by retinoic acid. Dev Biol 70, 515-521.
21. Sharova LV, Sharov AA, Piao Y, Shaik N, Sullivan T, Stewart CL, Hogan BL, and Ko MS (2007). Global gene expression profiling reveals similarities and differences among mouse pluripotent stem cells of different origins and strains. Dev Biol 307, 446-459.
22. Toumadje A, Kusumoto K-I, Parton A, Mericko P, Dowell L, Ma G, Chen L, Barnes DW, and Sato JD (2003). Pluripotent differentiation in vitro of murine ES-D3 embryonic stem cells. In Vitro Cell Dev Biol Anim 39, 449-453.
23. Wu H, Southam AD, Hines A, and Viant MR (2008). High-throughput tissue extraction protocol for NMR- and MS-based metabolomics. Anal Biochem 372, 204-212.
24. Hwang TL and Shaka AJ (1995). Water suppression that works - excitation sculpting using arbitrary waveforms and pulsed field gradients. J Magn Reson A 112, 275-279.
25. Thrippleton MJ, Edden RA, and Keeler J (2005). Suppression of strong coupling artefacts in J -spectra. J Magn Reson 174, 97-109.
26. Günther UL, Ludwig C, and Rüterjans H (2000). NMRLaB-advanced NMR data processing in MATLAB. J Magn Reson 145, 201-208.
27. 1H J -resolved nuclear magnetic resonance spectra for metabolomics. Anal Chim Acta 610, 80-88.
28. Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Scholer H, and Smith A (1998). Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95, 37-391.
29. Niwa H, Miyazaki J, and Smith AG (2000). Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24, 372-376.
30. Wobus AM, Holzhausen H, Jakel P, and Schoneich J (1984). Characterization of a pluripotent stem cell line derived from a mouse embryo. Exp Cell Res 152, 212-219.
31. Watanabe S, Umehara H, Murayama K, Okabe M, Kimura T, and Nakano T (2006). Activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate embryonic stem cells. Oncogene 25, 2697-2707.
32. Jirmanova L, Afanassieff M, Gobert-Gosse S, Markossian S, and Savatier P (2002). Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 expression and to the control of the G1/S transition in mouse embryonic stem cells. Oncogene 21, 5515-5528.
33. Lianguzova MS, Chuikin IA, and Pospelov VA (2004). PI 3-kinase activity is necessary for F9 mouse embryonic carcinoma cell proliferation. Tsitologiia 46, 26-34.
34. Podo F (1999). Tumour phospholipid metabolism. NMR Biomed 12, 413-439.
35. Ting YL, Sherr D, and Degani H (1996). Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res 16, 1381-1388.
36. Takahashi K, Murakami M, and Yamanaka S (2005). Role of the phosphoinositide 3-kinase pathway in mouse embryonic stem (ES) cells. Biochem Soc Trans 33, 1522-1525.
37. Paling NR, Wheadon H, Bone HK, and Welham MJ (2004). Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. J Biol Chem 279, 48063-48070.
38. Kim SJ, Cheon SH, Yoo SJ, Kwon J, Park JH, Kim CG, Rhee K, You S, Lee JY, Roh SI, et al. (2005). Contribution of the PI3K/Akt/PKB signal pathway to maintenance of self-renewal in human embryonic stem cells. FEBS Lett 579, 534-540.
39. Savatier P, Lapillonne H, Jirmanova L, Vitelli L, and Samarut J (2002). Analysis of the cell cycle in mouse embryonic stem cells. Methods Mol Biol 185, 27-33.
40. Lacal JC (2001). Choline kinase: a novel target for antitumor drugs. IDrugs 4, 419-426.
41. Reich R, Blumenthal M, and Liscovitch M (1995). Role of phospholipase D in laminin induced production of gelatinase A (MMP-2) in metastatic cells. Clin Exp Metastasis 2, 134-140.
42. Tortora G and Ciardiello F (2003). Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy. Ann N Y Acad Sci 1002, 236-243.
43. Mackay HJ and Twelves CJ (2007). Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 7, 554-562.
44. Spadaro F, Ramoni C, Mezzanzanica D, Miotti S, Alberti P, Cecchetti S, Iorio E, Dolo V, Canevari S, and Podo F (2008). Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res 68, 6541-6549.
45. Pardal R, Molofsky AV, He S, and Morrison SJ (2005). Stem cell self-renewal and cancer cell proliferation are regulated by common networks that balance the activation of proto-oncogenes and tumor suppressors. Cold Spring Harb Symp Quant Biol 70, 177-185.
46. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, and Chang HY (2008). Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2, 333-344.
47. Reya T, Morrison SJ, Clarke MF, and Weissman IL (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
48. Baharvand H, Fathi A, Gourabi H,Mollamohammadi S, and Salekdeh GH (2008). Identification of mouse embryonic stem cell-associated proteins. J Proteome Res 7, 412-423.
49. Fortunel NO, Otu HH, Ng HH, Chen J, Mu X, Chevassut T, Li X, Joseph M, Bailey C, Hatzfeld JA, et al. (2003). Comment on "'Stemness': transcriptional profiling of embryonic and adult stem cells" and "a stem cell molecular signature". Science 302, 393.
50. Kell DB (2006). Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discov Today 11, 1085-1092.